Global Anticoagulants Market 2021-2027

February 2022 | 80 pages | ID: G214472B9FFEEN
Gen Consulting Company

Abstracts

Anticoagulants are medicines that help prevent blood clots. They're given to people at a high risk of getting clots, to reduce their chances of developing serious conditions such as strokes and heart attacks. According to Gen Consulting Company, the global anticoagulants market is projected to reach USD 48,218 million, recording a CAGR of approximately 7.3 percent from 2021 to 2027.

The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into global anticoagulants market. It offers an exclusive insight into various details such as market size, key trends, competitive landscape, growth rate and market segments. This study also provides an analysis of the impact of the COVID-19 crisis on the anticoagulants industry.

The anticoagulants market is segmented on the basis of drug class, application, and region. The anticoagulants market is segmented as below:

By drug class:

• novel oral anticoagulants (NOACs)
• heparin and low-molecular weight heparin (LMWH)
• vitamin K antagonist

By application:

• atrial fibrillation/myocardial infarction (heart attack)
• deep vein thrombosis (DVT)
• pulmonary embolism (PE)
• others

By region:

• Asia Pacific
• Europe
• North America
• Rest of the World (RoW)

The report also provides a detailed analysis of several leading anticoagulants market vendors that include Alexion Pharmaceuticals, Inc., Aspen Pharmacare Holdings Limited, Bayer AG, Boehringer Ingelheim Pharmaceuticals Inc., Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Dr. Reddy's Laboratories Ltd., Johnson & Johnson, LEO Pharma A/S, Pfizer Inc., Sanofi SA, among others.

*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Historical & Forecast Period

This research report provides analysis for each segment from 2017 to 2027 considering 2020 to be the base year.

Scope of the Report

• To analyze and forecast the market size of the global anticoagulants market.
• To classify and forecast the global anticoagulants market based on drug class, application, and region.
• To identify drivers and challenges for the global anticoagulants market.
• To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global anticoagulants market.
• To identify and analyze the profile of leading players operating in the global anticoagulants market.

Why Choose This Report

• Gain a reliable outlook of the global anticoagulants market forecasts from 2021 to 2027 across scenarios.
• Identify growth segments for investment.
• Stay ahead of competitors through company profiles and market data.
• The market estimate for ease of analysis across scenarios in Excel format.
• Strategy consulting and research support for three months.
• Print authentication provided for the single-user license.

Contents

PART 1. INTRODUCTION

1.1 Market definition
1.2 Key benefits
1.3 Market segment

PART 2. METHODOLOGY

2.1 Primary
2.2 Secondary

PART 3. EXECUTIVE SUMMARY

PART 4. MARKET OVERVIEW

4.1 Introduction
4.2 Market dynamics
  4.2.1 Drivers
  4.2.2 Restraints

PART 5. GLOBAL MARKET FOR ANTICOAGULANTS BY DRUG CLASS

5.1 Novel oral anticoagulants (NOACs)
  5.1.1 Market size and forecast
5.2 Heparin and low-molecular weight heparin (LMWH)
  5.2.1 Market size and forecast
5.3 Vitamin K antagonist
  5.3.1 Market size and forecast

PART 6. GLOBAL MARKET FOR ANTICOAGULANTS BY APPLICATION

6.1 Atrial fibrillation/myocardial infarction (heart attack)
  6.1.1 Market size and forecast
6.2 Deep vein thrombosis (DVT)
  6.2.1 Market size and forecast
6.3 Pulmonary embolism (PE)
  6.3.1 Market size and forecast
6.4 Others
  6.4.1 Market size and forecast

PART 7. GLOBAL MARKET FOR ANTICOAGULANTS BY REGION

7.1 Asia Pacific
  7.1.1 Market size and forecast
7.2 Europe
  7.2.1 Market size and forecast
7.3 North America
  7.3.1 Market size and forecast
7.4 Rest of the World (RoW)
  7.4.1 Market size and forecast

PART 8. KEY COMPETITOR PROFILES

8.1 Alexion Pharmaceuticals, Inc.
8.2 Aspen Pharmacare Holdings Limited
8.3 Bayer AG
8.4 Boehringer Ingelheim Pharmaceuticals Inc.
8.5 Bristol-Myers Squibb Company
8.6 Daiichi Sankyo Company, Limited
8.7 Dr. Reddy's Laboratories Ltd.
8.8 Johnson & Johnson
8.9 LEO Pharma A/S
8.10 Pfizer Inc.
8.11 Sanofi SA
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
DISCLAIMER
ABOUT GEN CONSULTING COMPANY